

Poster Session #1

Classification	#	Last Name	First Name	Title of Abstract
E	1	Ragnarsson-Olding	Boel	Ano-rectal malignant melanomas within a population based national patient series in Sweden during 40 years: Anatomical sites, tumor density, incidence, gender differences, geographic distribution and survival
E	2	Cockburn	Myles	Sun exposure behaviors and risk of superficial spreading and nodular melanoma
E	3	Francishcetto	Thiago	Prognostic evaluation of cutaneous melanoma patients with lymph node micrometastasis treated in the national cancer institute (INCA) Brazil
E	4	Han	Jiali	Comprehensive screening of genetic variants in DNA repair pathways and melanoma risk
E	5	Legge	Matthew	Kidskin II: Moles and Genes, the Genetic Epidemiology of Melanocytic Naevi in Children
E	6	Manga	Prashiela	A role for the oculocutaneous albinism type 2 gene in determination of melanoma susceptibility
E	7	Pjanova	Dace	Prevalence of the CDKN2A and CDK4 mutations in incidence case melanoma patients from Latvia
E	8	Polsky	David	Frequent genetic and epigenetic inactivation of p14ARF in human melanoma
E	9	Prats	Alejandro	Research of G2817A and T538C polymorphisms in 95 patients with melanoma
M	10	Warycha	Melanie	Differential expression of insulin-like growth factor binding protein-4(IGFBP-4) and integrin alpha-v-beta3 in melanoma progression
M	11	Bataille	Veronique	Large numbers of nevi are associated with longer telomeres in white blood cells and may be a marker of delayed senescence in vivo
M	12	Baumgartner	Joel	Increased survival from StageIV melanoma associated with fewer regulatory T cells
M	13	Demerais	Florence	GSTT1 null variant decreases melanoma risk in presence of CDKN2A mutations, MC1R variants and host factors in French melanoma-prone pedigrees
M	13	Yu	Jesse	Differential expression of insulin-like growth factor binding protein-4(IGFBP-4) and integrin alpha-v-beta3 in melanoma progression
M	14	Eichoff	Ossia	Proliferative and invasive signature melanoma cells maintain phenotype both in vivo and in vitro
M	15	French	Amanda	Subcellular distribution of claudin-1 is related to invasive capacity in melanoma
M	16	Gartside	Michael	Loss of function FGFR2 mutations in melanoma
M	17	Markel	Gal	Dynamic CEACAM1 expression enhances protection of melanoma cells from specific ongoing immune attack
M	18	Ozanne	Bradford	Melanoma specific expression of the Rac-specific GEF, P-Rex1, controls the mode of motility melanoma derived cell lines use during invasion

Poster Session #1

Classification	#	Last Name	First Name	Title of Abstract
M	19	Sa de Araujo	Marcelo	Four years experience cutaneous melanoma submitted to sentinel lymph node biopsy in the nacional cancer institute (INCA) - Brazil
M	20	Vantuchova	Yvette	Vulvovaginal melanoma
M	21	Takata	Minoru	Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and Spitzoid tumors
M	22	van Kilsdonk	Jeroen WJ	Activated leukocyte cell adhesion molecule (CD166/MEMD), a sensor of cell density controlling invasive growth
M	24	Was	H	Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice
M	25	Yancovitz	Mollie	Detection of BRAF mutations in plasma and tissues of patients with metastatic tumors
T	26	Bedikian	Agop	The AGENDA Study: a randomized, double-blind study of Genasense plus dacarbazine (DTIC) in chemotherapy-naive patients with advanced melanoma and low LDH
T	27	Schweitzer	Andrew	Computer-simulated therapy of metastatic melanoma tumors with wide range of melanin concentrations with a radiolabeled melanin-binding antibody
T	28	Schachter	Jacob	Modifying IL-2 concentrations during culture improves function of T cells for adoptive immunotherapy of
T	29	Cadilli	Ali	Prediction of non-sentinel lymph node metastasis in malignant melanoma
T	30	Friedman	Kent	3D rendered PET/CT for preoperative assessment of locally recurrent melanoma
T	31	Heller	Richard	Enhanced delivery of plasmid IL-12 by electroporation for treatment of malignant melanoma: results of first human
T	32	Howell	RC	Tumor melanin-binding heptapeptides with low kidney uptake as potential vehicles for targeted radionuclide therapy of metastatic melanoma
T	33	Gilles	Erard	Progression-free survival (PFS) with an oblimersen-dacarbazine (OBL-DTIC) regimen in advanced melanoma: PFS difference is not explained by
T	34	Kikuchi	Kanako	Serum 5-S-cysteinyldopa levels in psoriasis patients under narrowband ultraviolet-B phototherapy
T	35	Leachman	Sancy	A preliminary study of the design and feasibility of melanoma prevention trials
T	36	Ocvirk	Janja	Temozolomide in the treatment of patients with multiple melanoma brain metastases after whole brain
T	37	O'Day	Steve	Analysis of the duration and kinetics of response of ipilimumab in patients with stage II/IV malignant
T	38	Ono	Ichiro	Development of therapeutic modality and environment for chem-thermo-immuno (CTI) therapy using

Poster Session #1

Classification	#	Last Name	First Name	Title of Abstract
T	39	Pavlick	Anna	A phase I study of the triple combination of oblimersen (OBL), temozolomide (TMZ) and abraxane (ABX) in patients with advanced melanoma and normal LDH
R	40	Yang	Sun	Ref-1 deficiency inhibits cellular transformation and metastatic potential of human melanoma cells
R	41	Botton	Thomas	Ciglitazone, a PPARgamma ligand, inhibits the growth of melanomas but not normal melanocytes through cell cycle arrest and apoptotic mechanisms
R	42	Lillehammer	Trine	Adenoviral delivery of PAI-1 to a human melanoma cell line results in reduced migratory properties in vitro and
R	43	Blackburn	Jessica	RNAi inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing angiogenesis and
R	44	Bowling	Benjamin	Inhibition of mitochondrial protein translation sensitizes melanoma cells to arsenic trioxide (ATO) cytotoxicity via a reactive oxygen species (ROS) dependent mechanism
R	45	Busch	Christain	Influence of BMP-2 and its antagonist noggin on physiological neural crest migration and invasive growth of malignant melanoma cells in the chick embryo
R	46	Chen	Suzie	Metabotropic glutamate receptor 1 (Gm1) is a molecular target for melanoma
R	47	Del Vecchio	M	Engineering OKT3 blasts to express GD2 specific
R	48	D'Orazio	John	Rescue of a UV-protective phenotype in a fair-skinned animal model by topical application of forskolin
R	49	Doudican	Nicole	Mebendazole induces melanoma apoptosis through tubulin disruption and phosphorylation of BCL-2
R	50	Fields	Gregg	Targeting nanoDDSs utilizing mini-collagen ligands recognized by CD44/CSPG melanoma receptors
R	51	Ghosh	Rita	Catechols modulate proliferation and apoptosis in
R	52	Herlyn	Dorothee	Novel melanoma-associated antigens with vaccine
R	53	Hsu	Mei-Yu	Coordinated noggin upregulation renders resistance to BMP7-mediated autocrine growth inhibition in advanced
R	54	Ivanov	Vladimir	Resveratrol sensitizes human melanomas to TRAIL through regulation of APC1/cJun, STAT3, and NF-kappa B transcription factors and modulation of apoptotic gene expression in conditions of genetic suppression of
R	55	Jorgensen	Kjersti	Inhibition of SRC prevents suspension induced cell death of WM35 melanoma cells
R	56	Kiss	Robert	The alpha1 sodium pump subunit: a new target to combat
R	57	Kreis	Stephanie	IL-24 and constitutively active STAT3: involvement in the survival of melanoma cells
R	58	Lucas	Keryn	MCL-1 determines sensitivity of melanomas to BH3-
R	59	Marone	Romina	Phosphoinositide 3-kinase pathway - promising drug
R	60	Mathieu	Veronique	Galectin-1 knockdown increases sensitivity to temozolomide and impairs angiogenesis in a B16F10
R	61	McDaid	Ronan	A paradigmatic approach for melanocytic transformation: Activation of MAPK pathway and loss of p53 function
R	62	Bertin	John	STA-4783 induces apoptosis and enhances the anticancer activity of paclitaxel through induction of

Poster Session #1

Classification	#	Last Name	First Name	Title of Abstract
R	63	Meier	Friedegund	Inhibition of p13K-AKT-mTOR but not RAF-MEK-ERK signalling sensitizes melanoma cells to cisplatin and
R	64	Miller	Leslie A	Lipid-lowering medications potentiate temozolomide to synergistically induce human melanoma cell death
R	65	Norris	David	Hyperthermia induces endoplasmic reticulum mediated apoptosis in melanoma cells
R	66	Oy	Geir Frode	Inhibition of TGF-beta signaling in melanoma cell lines by the small molecular inhibitor LY2109761
R	67	Salinas-Jazmin	Nohemi	Preclinical studies of 4-hydroxycoumarin in a murine
R	68	Schaider	Helmut	Stage specific effects of HGF on Snail, Slug, Twist and
R	69	Slominski	Andrez	Melanogenesis and melanoma: experimental and clinical
R	70	Smalley	Keiran SM	Identificaiton of BRAF/N-Ras wild-type melanomas that overexpress CDK4/c-Kit and respond to Imatinib
R	71	Smith	Paul	Molecular determinants of the response of melanoma cell lines to the MEK 1/2 inhibitor AZD6244 (ARRY-142886)
R	72	Timar	Josef	EGFR mutations in human melanoma and sensitivity to
R	73	Verhaegen	Monique	Genetic and pharmacological approaches to define the role of the p53-MDM2 axis in melanoma cell
R	74	Wachsman	William	A non-invasive EGIR-based genomic assay discriminates melanoma from atypical nevi
R	75	Wahl	Miriam	Acid transporters as targets for melanoma treatment
R	76	Yamashita	Toshiharu	Magnetite-conjugated cysteaminyphenol as a novel nanoparticle vector for melanoma-directed drug delivery